[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanol

We are [4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanol CAS:118175-10-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanol
CAS.NO:118175-10-3
Synonyms:[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanol
(4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methanol
2-Hydroxymethyl-3-methyl-4-(3-methoxypropanoxyl)pyridine
2-HYDROXYMETHYL-4-METHOXYPROPOXY-3-METHYLPYRIDINE
2-Hydroxymethyl-4-(3-methoxypropoxy)-3-methylpyridine
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 342.8±37.0 °C at 760 mmHg
Molecular Formula C11H17NO3
Molecular Weight 211.258
Flash Point 161.1±26.5 °C
 
Specification:
Appearance:Off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Rabeprazole(CAS:117976-89-3).

[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanol


Related News: If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such.121660-11-5 Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.5-Chloro-2-methoxypyridine In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.2-Amino-3-methylphenol In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.

Related Products
Product Name
2-Isopropoxy-5-methyl-4-(piperidin-4-yl)aniline dihydrochloride hydrate View Details
N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline View Details
1-(2,4,6-Triisopropylphenylsulfonyl)imidazole View Details
4-methoxy-2-oxo-1H-pyridine-3-carbonitrile manufacturer 4-Bromo-2,3-difluorobenzaldehyde manufacturer 2-Bromo-5-(hydroxy)benzaldehyde manufacturer tetrabutylammonium bromide manufacturer 5-(2-Bromoethyl)-2,3-Dihydrobenzofuran manufacturer